10 likes | 141 Views
Finish study. Responders (BP < 130/80). Monotherapy * Eprosartan 600 vs. Ramipril 5. BP ≥ 130/80 - ≤ 150/90. Non-responders (BP ≥ 130/80). Double-combination therapy * Eprosartan/HCTZ 600/12.5 vs. Ramipril/HCTZ 5/12.5. Hypertension
E N D
Finish study Responders (BP < 130/80) Monotherapy* Eprosartan 600 vs. Ramipril 5 BP ≥ 130/80 - ≤ 150/90 Non-responders (BP ≥ 130/80) Double-combination therapy* Eprosartan/HCTZ 600/12.5 vs. Ramipril/HCTZ 5/12.5 Hypertension + DM type 2 Responders (BP < 130/80) BP > 150/90 - ≤ 179/109 Double-combination therapy* Eprosartan/HCTZ 600/12.5 vs. Ramipril/HCTZ 5/12.5 Non-responders (BP≥ 130/80) Triple-combination therapy* Epro./HCTZ/Moxo 600/12.5/0.4 vs. Ramipril/HCT/Moxo 5/12.5/0.4 R 1 week 2 weeks 4 weeks 8 weeks Screening Placebo Mono- or double-combination therapy Combination therapy with two-, adjusted to severity of hypertension respectively three agents in non-responders of the four initial arms * - Eprosartan and Ramipril to be administered together with corresponding placebo (double-dummy technique).